PGP and cancer: Although P-gp inhibitors showed high efficacy in vitro and in vivo studies, very few have successfully passed all phases of the clinical trials and none of them have been approved by the U.S. Food and Drug Administration (FDA) for clinical use in cancer treatment (Nanayakkara et al., 2018; Robinson and Tiriveedhi, 2020).